舒利迭治疗慢性阻塞性肺病的临床应用研究

目的对比研究舒利迭（沙美特罗／丙酸氟替卡松）治疗慢性阻塞性肺疾病（COPD）疗效。方法对300例确诊为COPD的患者分成3组：分别吸入舒利迭（实验组）、辅舒酮（对照组1）、辅舒酮加万托林（对照组2），根据圣．乔治（St．George）呼吸疾病问卷（SGRQ）的方法对临床症状问卷调查及体征检查评分；测定肺功能指标FEV1、FEV1／FVC及FEV1占预计值的百分率（％），评价治疗前后肺功能的变化。结果与单独应用辅舒酮组比较，辅舒酮加万托林组治疗后临床症状积分及上述肺功能指标的改善更加显著（P〈0．05）；而与单独应用辅舒酮组比较，舒利迭组治疗后临床症状积分及上述肺功能指标的改善更具优势（P〈0．01）；并且与辅舒酮加万托林组比较，舒利迭组治疗后临床症状积分及上述肺功能指标的改善也更加显著（P〈0．05）。结论舒利迭对COPD的疗效明显优于应用其单一组分，也优于其他复方制剂，可以认为是目前临床治疗COPD的理想药物。

Clinical application study of seretide in treatment of chronic obstructive pulmonary diseases( CO PD )

[Objective] To investigate the curative effect of seretide(salmeterol/fluticasone propionate) in the treatment of obstructive pulmonary diseases(COPD) by comparison. [Methods] 300 patients who sufferred from COPD were divided into 3 groups:experiment group(inhale seretide), control group 1(inhale flixotide) and control group 2(inhale flixotide and albuterol aerosol). According to the methods of standard grade of respiratory diseases questionnaire (SGRQ) introduced by St. George, the clinical symptom questionnaire and physical sign survey were graded.Subsequently, the percentage of pulmonary functional parameters including FEV1, FEV1 or FVC and FEV1 in the anticipation value(%) were examined and then the pulmonary functional changes before and after therapy were evaluated. [Results] Clinical symptom integral and the above-mentioned pulmonary functional parameters in the flixotide and albuterol aerosol group were improved more significantly than those in the single flixotide group.Moreover,the curative effect of the seretide group excelled that of the single flixotide group(P <0.01) and of the flixotide and albuterol aerosol group(P <0.05). [Conclusions] Seretide can presently serve as the most ideal medicine for COPD due to its more significant curative effect than that of the single composition or the other compound preparation.